Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers

NCT ID NCT07002112

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing a new gene therapy that reprograms a patient's own immune cells to attack two targets (CD19 and CD20) on cancer cells. The trial will enroll 30 adults with B-cell cancers that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the therapy shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19/CD20 dual-target CAR-T lentiviral product (a type of gene therapy that reprograms a patient's own immune cells to attack cancer cells)
What this could lead to: If successful, this could provide a new treatment option for patients with hard-to-treat B-cell cancers that have not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. There is a risk of serious side effects, and the therapy may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY B-CELL MALIGNANCIES

Contacts and locations

Locations

Beijing Gobroad Boren Hospita
RECRUITING

Beijing, Beijing Municipality, 102206, China
The First Affiliated Hospital of USTC west district
RECRUITING

Hefei, Anhui, 230000, China
The First Affiliated Hospital of ZHENGZHOU University
NOT_YET_RECRUITING

Zhengzhou, Henan, 450000, China
The First Affiliated Hospital with Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210029, China
The Fourth Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, 050000, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.